News coverage about Rockwell Medical (NASDAQ:RMTI) has been trending positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rockwell Medical earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.8013132179596 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
RMTI has been the subject of a number of analyst reports. Zacks Investment Research upgraded Rockwell Medical from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a research report on Wednesday, October 25th. BidaskClub upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Friday, December 15th.
Shares of Rockwell Medical (NASDAQ:RMTI) opened at $5.86 on Friday. The company has a market capitalization of $303.32, a PE ratio of -13.63 and a beta of 2.02. Rockwell Medical has a 1 year low of $5.06 and a 1 year high of $8.98.
Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Wednesday, November 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Rockwell Medical had a negative return on equity of 46.63% and a negative net margin of 39.28%. The firm had revenue of $14.63 million during the quarter, compared to analysts’ expectations of $13.33 million. During the same quarter last year, the business posted ($0.09) earnings per share. The firm’s revenue was up 14.2% on a year-over-year basis. analysts forecast that Rockwell Medical will post -0.44 earnings per share for the current fiscal year.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.